According to DelveInsight, the Glioblastoma treatment pipeline includes over 180 key companies actively engaged in developing more than 200 therapeutic candidates for the condition.
Glioblastoma Overview:
Glioblastoma Multiforme (GBM) is the most prevalent primary brain tumor in adults and is known for its extremely poor prognosis, despite improvements in diagnostic tools and treatment strategies. The disease progresses through somatic evolution, where genetic mutations accumulate, causing the tumor cells’ genome to differ significantly from that of normal cells. GBM arises from a complex interplay of molecular and genetic changes that disrupt key signaling pathways. Its aggressive behavior is driven by its ability to infiltrate surrounding brain tissue, making full surgical removal nearly impossible, and by its high degree of vascularization, which contributes to its malignancy.
Patients with GBM often experience vague symptoms such as headaches, personality changes, nausea, or symptoms resembling a stroke. Common neurological manifestations include vomiting, seizures, cognitive impairments, focal deficits, and cranial nerve dysfunction. In rare instances, vertigo or psychiatric symptoms may occur. GBM accounts for approximately 52% of all primary brain tumors and 20% of all tumors within the cranial cavity, making it the most common and aggressive form of primary brain cancer.
Request for a detailed insights report on Glioblastoma pipeline insights
“Glioblastoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Therapeutics Market.
Key Takeaways from the Glioblastoma Pipeline Report
DelveInsight’s Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
In March 2025, Laminar Pharmaceuticals revealed a Phase 2 clinical trial for LAM561 and TMZ. The planned Phase IIB/III randomized, double-blind, placebo-controlled study in patients with newly diagnosed primary glioblastoma multiforme (ndGBM) seeks to evaluate the efficacy and safety of LAM561 versus placebo, in combination with the standard treatment of radiation therapy and temozolomide (TMZ). This will be followed by a six-month adjuvant treatment period with TMZ and then LAM561 or placebo as monotherapy.
In March 2025, TVAX Biomedical announced Phase 2 and 3 clinical trials for Temozolomide. This randomized study aims to compare the combination of TVI-Brain-1 immunotherapy with standard therapy against standard therapy alone for newly diagnosed MGMT unmethylated glioblastoma patients. The treatment involves using the patient’s own cancer cells, collected post-surgery, to create a vaccine that stimulates an immune response, significantly boosting the number of cancer neoantigen-specific effector T cell precursors in the patient’s body.
Key Glioblastoma companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others are evaluating new drugs for Glioblastoma to improve the treatment landscape.
Promising Glioblastoma pipeline therapies in various stages of development include Enzastaurin, Asunercept, Berubicin, VXM01, Azeliragon, MB-101, and others.
Glioblastoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Glioblastoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Glioblastoma market.
Download our free sample page report on Glioblastoma pipeline insights
Glioblastoma Emerging Drugs
Enzastaurin: Denovo BioPharma
Asunercept: Apogenix
Berubicin: CNS Pharmaceuticals
VXM01: VAXIMM
Azeliragon: Cantex
MB-101: Mustang Bio
Glioblastoma Companies
More than 180 major companies are actively involved in developing treatments for Glioblastoma. Among them, Denovo is one of the companies with drug candidates currently in the most advanced stage of development—Phase III clinical trials.
DelveInsight’s report covers around 200+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Glioblastoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Glioblastoma Therapies and Key Companies: Glioblastoma Clinical Trials and advancements
Glioblastoma Pipeline Therapeutic Assessment
• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage
• Glioblastoma Assessment by Route of Administration
• Glioblastoma Assessment by Molecule Type
Download Glioblastoma Sample report to know in detail about the Glioblastoma treatment market @ Glioblastoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioblastoma Current Treatment Patterns
4. Glioblastoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Late-Stage Products (Phase-III)
7. Glioblastoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Discontinued Products
13. Glioblastoma Product Profiles
14. Glioblastoma Key Companies
15. Glioblastoma Key Products
16. Dormant and Discontinued Products
17. Glioblastoma Unmet Needs
18. Glioblastoma Future Perspectives
19. Glioblastoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Glioblastoma Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
